MapLight Therapeutics, Inc. Share Price

MapLight Therapeutics, Inc. Share Price

NASDAQ: MPLT | Micro Cap
$8.08
+$0.10 (1.25%) Last updated on 29 Oct, 2026 | 20:38 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

MapLight Therapeutics, Inc. Stock Performance

Open
$8.15
Prev. Close
$7.98
Circuit Range
N/A
Day Range
$8.14 - $8.17
Year Range
$7.48 - $39.82
Volume
1,128
Average Traded
$8.16

MapLight Therapeutics, Inc. Share Price Today

As of 29 October 2026, MapLight Therapeutics, Inc.'s share price is $8.08. The stock opened at $8.15, compared to its previous close of $7.98. During today's trading session, MapLight Therapeutics, Inc.'s share price traded between $8.14 and $8.17, with an average price of $8.16. Over the past 52 weeks, the stock has recorded a high of $39.82 and a low of $7.48. In terms of performance, MapLight Therapeutics, Inc.'s share price has declined by 74.55% over the last six months and is down 52.48% on a year-on-year basis.

MapLight Therapeutics, Inc. Share Price Chart

Line chart of the MapLight Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 8.01 to 8.17, ending at 8.08.
$8.14$8.17
L
Show Current Price
H

MapLight Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$70.14M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-4.14
Revenue (TTM)
$0.00
Return On Equity (TTM)
-65.99%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
N/A

MapLight Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00
Net Profit-$79.55-$60.67-$60.19
Net Profit MarginN/AN/AN/A
Income ChangeN/A23.73%0.79%

MapLight Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2025
Revenue$0.00
Net Profit-$161.15
Net Profit MarginN/A
Income ChangeN/A

About MapLight Therapeutics, Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

MapLight Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$10.12
$8.14
-20.20%
Sep 2026
$12.95
$10.20
-18.40%
Aug 2026
$12.70
$12.50
-4.03%
Jul 2026
$34.43
$13.03
-63.68%
Jun 2026
$28.73
$35.86
+22.26%
May 2026
$31.48
$29.33
-7.62%
Apr 2026
$21.00
$31.75
+56.02%
Mar 2026
$17.50
$20.35
+17.77%
Feb 2026
$17.45
$17.28
-2.37%
Jan 2026
$17.29
$17.70
+0.97%
Dec 2025
$13.19
$17.53
+27.54%
Nov 2025
$16.80
$13.74
-19.17%

MPLT Share Price FAQs